Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2.
暂无分享,去创建一个
Ali Azizi | Francisco Diaz-Mitoma | Antonio Giulivi | Ikuri Alvarez-Maya | Masoud Ghorbani | L. Babiuk | R. Kothary | Y. De Repentigny | F. Diaz-Mitoma | I. Álvarez-Maya | M. Lapner | A. Giulivi | Yves De Repentigny | Rashmi Kothary | C. Soare | A. Azizi | Turaya Naas | Michael Lapner | Susantha Gomes | Lorne Babiuk | Catalina Soare | M. Ghorbani | Turaya Naas | S. Gomes
[1] M. Honda,et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. , 2002, Gastroenterology.
[2] P. Marcellin,et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) , 1998, Lancet.
[3] D. Tyrrell,et al. Hepatitis C virus replication in mice with chimeric human livers , 2001, Nature Medicine.
[4] J. Hoofnagle,et al. Hepatitis C: The clinical spectrum of disease , 1997, Hepatology.
[5] M. Boiocchi,et al. Hepatitis C Virus, B-cell Proliferation and Lymphomas , 2002, Leukemia & lymphoma.
[6] J. George,et al. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response , 2002, Hepatology.
[7] S. Polyak,et al. Treatment of chronic hepatitis C virus infection: a clinical and virological perspective. , 1996, Advances in experimental medicine and biology.
[8] J. Hoefs,et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.
[9] D. Wendling,et al. Presence of hepatitis C virus RNA in the salivary glands of patients with Sjögren's syndrome and hepatitis C virus infection. , 2002, The Journal of rheumatology.
[10] J. McLauchlan,et al. Sequence motifs required for lipid droplet association and protein stability are unique to the hepatitis C virus core protein. , 2000, The Journal of general virology.
[11] Darius Moradpour,et al. Structural biology of hepatitis C virus , 2004, Hepatology.
[12] H. Yonekawa,et al. Repeated hepatocyte injury promotes hepatic tumorigenesis in hepatitis C virus transgenic mice , 2003, Cancer science.
[13] C. Rice,et al. Processing in the hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2-specific products with different C termini , 1994, Journal of virology.
[14] S. Ueda,et al. Expression of hepatitis C virus core protein associated with malignant lymphoma in transgenic mice. , 2003, Comparative immunology, microbiology and infectious diseases.
[15] E. Holmes,et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. , 1993, The Journal of general virology.
[16] M. Honda,et al. A transgenic mouse model of steatosis and hepatocellular carcinoma associated with chronic hepatitis C virus infection in humans. , 2000, Transactions of the American Clinical and Climatological Association.
[17] M. Koffler. Epidemiology of hepatitis. , 1965, Lancet.
[18] N. Kato. Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation. , 2000, Microbial & comparative genomics.
[19] M. Mondelli,et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study , 1997, Hepatology.
[20] T. Morizane,et al. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection , 1998, The Lancet.
[21] O. Yokosuka,et al. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients , 1995, Hepatology.
[22] P. Marcellin,et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.
[23] J. Morales,et al. Hepatitis C virus infection and renal disease after renal transplantation. , 2004, Transplantation proceedings.
[24] R. Bartenschlager,et al. Kinetic and structural analyses of hepatitis C virus polyprotein processing , 1994, Journal of virology.
[25] J Cohen,et al. The Scientific Challenge of Hepatitis C , 1999, Science.
[26] S. Levy,et al. V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. , 2001, Blood.
[27] R. Purcell,et al. Genetic heterogeneity of the hepatitis C virus. , 1995, Princess Takamatsu symposia.
[28] M. Gambardella,et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity , 2001, Hepatology.
[29] K. Koike,et al. Expression of hepatitis C virus envelope proteins in transgenic mice. , 1995, The Journal of general virology.
[30] M. Selby,et al. Interaction between hepatitis C virus core protein and E1 envelope protein , 1996, Journal of virology.
[31] M. Moriyama,et al. Irregular regeneration of hepatocytes is an important factor in the hepatocarcinogenesis of liver disease , 2001, Hepatology.
[32] K. Chayama,et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis , 1993, Hepatology.
[33] F. Chisari. Cytotoxic T cells and viral hepatitis. , 1997, The Journal of clinical investigation.
[34] D. Pessayre,et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral‐related steatosis , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[35] H. Yonekawa,et al. Efficient Conditional Transgene Expression in Hepatitis C Virus cDNA Transgenic Mice Mediated by the Cre/loxP System* , 1998, The Journal of Biological Chemistry.
[36] M. Kohara,et al. Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates , 1999, Hepatology.
[37] G. Migliaccio,et al. Biosynthesis and biochemical properties of the hepatitis C virus core protein , 1994, Journal of virology.
[38] N. Tanaka,et al. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis , 1996, Journal of Gastroenterology.
[39] K. Koike,et al. Sialadenitis histologically resembling Sjogren syndrome in mice transgenic for hepatitis C virus envelope genes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[40] C. Tinelli,et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. , 1996, Gastroenterology.
[41] D. Pateron,et al. Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease , 1992, The Lancet.
[42] K Koike,et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. , 1997, The Journal of general virology.
[43] K. Eguchi,et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection , 2003, Cancer.
[44] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[45] M. Makuuchi,et al. Increase in the concentration of carbon 18 monounsaturated fatty acids in the liver with hepatitis C: analysis in transgenic mice and humans. , 2001, Biochemical and biophysical research communications.
[46] K. Abid,et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. , 2000, Journal of hepatology.
[47] Miriam J. Alter. Epidemiology of hepatitis C. , 1996 .
[48] C. Rice,et al. Expression and identification of hepatitis C virus polyprotein cleavage products , 1993, Journal of virology.
[49] P. Barr,et al. Genetic organization and diversity of the hepatitis C virus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.